Publications by authors named "Karen Small"

Claim this Profile
C
Chronic Eye Redness and Pain After 9 Months of Anti-inflammatory Therapy.
Karen Small, Andrew Stephenson, C Stephen Foster

JAMA Ophthalmol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Visual Outcome of Refractory Retinal Vasculitis Associated With Antineutrophil Cytoplasm Antibody-Associated Vasculitides.
Miaoli Lin, Stephen D Anesi, Lina Ma, Aseef Ahmed, Karen Small

Am J Ophthalmol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Monica M Mita, Alain C Mita, Jennifer L Moseley, Jennifer Poon, Karen A Small

Br J Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia.
Paolo Ghia, Lydia Scarfò, Susan Perez, Kumudu Pathiraja, Martha Derosier, Karen Small

Blood· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Claire Fabre, Marco Gobbi, Cyrine Ezzili, Mustapha Zoubir, Marie-Paule Sablin, Karen Small

Cancer Chemother Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
Monica M Mita, Anil A Joy, Alain Mita, Kamalesh Sankhala, Ying-Ming Jou, Karen Small

Clin Breast Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Joe J Stephenson, John Nemunaitis, Anil A Joy, Julie C Martin, Ying-Ming Jou, Karen Small

Lung Cancer· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J Feldman, Swaminathan Padmanabhan Iyer, Karen Small

Cancer Chemother Pharmacol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
John J Nemunaitis, Karen A Small, Paul Kirschmeier, Da Zhang, Yali Zhu

J Transl Med· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Da Zhang, Monica Mita, Geoffrey I Shapiro, Jennifer Poon, Karen Small

Cancer Chemother Pharmacol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effectiveness of a specialized trauma course in the knowledge base and level of job satisfaction in emergency nurses.
Kate Bailey, Michelle Swinyer, Michael Bard, Vicki Sparrow, Jennifer Deegan, Karen Small

J Trauma Nurs· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis